Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 5
2004 1
2005 2
2006 4
2007 2
2008 3
2009 5
2010 9
2011 10
2012 9
2013 21
2014 24
2015 16
2016 16
2017 13
2018 21
2019 8
2020 13
2021 11
2022 10
2023 19
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Results by year

Filters applied: . Clear all
Page 1
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. Piha-Paul SA, et al. Among authors: tsimberidou am. Oncologist. 2024 Apr 4;29(4):e514-e525. doi: 10.1093/oncolo/oyad338. Oncologist. 2024. PMID: 38297981 Free PMC article. Clinical Trial.
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EEI, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, Yuan Y, Meric-Bernstam F, Naing A. Subbiah V, et al. Among authors: tsimberidou am. Cancer Res Commun. 2024 Feb 12;4(2):378-387. doi: 10.1158/2767-9764.CRC-22-0260. Cancer Res Commun. 2024. PMID: 38126764 Free PMC article. Clinical Trial.
Autologous engineered T cell receptor therapy in advanced cancer.
Tsimberidou AM, Baysal MA, Chakraborty A, Andersson BS. Tsimberidou AM, et al. Hum Vaccin Immunother. 2023 Dec 15;19(3):2290356. doi: 10.1080/21645515.2023.2290356. Epub 2023 Dec 19. Hum Vaccin Immunother. 2023. PMID: 38114231 Free PMC article. Review.
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Knisely A, et al. Among authors: tsimberidou am. Cancer. 2024 Feb 1;130(3):400-409. doi: 10.1002/cncr.35063. Epub 2023 Oct 21. Cancer. 2024. PMID: 37864520 Clinical Trial.
Recommendations for Cell-Free DNA Assay Validations: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.
Lockwood CM, Borsu L, Cankovic M, Earle JSL, Gocke CD, Hameed M, Jordan D, Lopategui JR, Pullambhatla M, Reuther J, Rumilla KM, Tafe LJ, Temple-Smolkin RL, Terraf P, Tsimberidou AM. Lockwood CM, et al. Among authors: tsimberidou am. J Mol Diagn. 2023 Dec;25(12):876-897. doi: 10.1016/j.jmoldx.2023.09.004. Epub 2023 Oct 6. J Mol Diagn. 2023. PMID: 37806433 Review.
Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation.
Chelariu-Raicu A, Piha-Paul SA, Chavez-MacGregor M, Johnson J, Sawaya R, McAleer MF, Nguyen A, Hartnett A, Tsimberidou AM, Meric-Bernstam F, Dumbrava EE. Chelariu-Raicu A, et al. Among authors: tsimberidou am. J Immunother Precis Oncol. 2023 Jun 28;6(3):158-161. doi: 10.36401/JIPO-22-33. eCollection 2023 Aug. J Immunother Precis Oncol. 2023. PMID: 37637237 Free PMC article.
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
Piha-Paul SA, Tseng C, Tran HT, Gao M, Karp DD, Subbiah V, Tsimberidou AM, Kawedia JD, Fu S, Pant S, Yap TA, Morris VK, Kee BK, Blum Murphy M, Lim J, Meric-Bernstam F. Piha-Paul SA, et al. Cancer Chemother Pharmacol. 2023 Aug;92(2):107-118. doi: 10.1007/s00280-023-04545-4. Epub 2023 Jun 14. Cancer Chemother Pharmacol. 2023. PMID: 37314501 Free PMC article. Clinical Trial.
205 results